These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 21243000)

  • 21. Video-Urodynamic Characteristics and Predictors of Switching from Botulinum Neurotoxin a Injection to Augmentation Enterocystoplasty in Spinal Cord Injury Patients.
    Lin CC; Kuo HC
    Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
    Chenet A; Perrouin-Verbe B; Le Normand L; Labat JJ; Brunel P; Lefort M; Mathé JF
    Ann Readapt Med Phys; 2007 Nov; 50(8):651-60. PubMed ID: 17490775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concomitant Detrusor and External Urethral Sphincter Botulinum Toxin-A Injections in Male Spinal Cord Injury Patients with Detrusor Overactivity and Detrusor Sphincter Dyssynergia.
    Huang YH; Chen SL
    J Rehabil Med; 2022 Mar; 54():jrm00264. PubMed ID: 35174865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of detrusor botulinum toxin a injection on urothelial dysfunction in patients with chronic spinal cord injury: a clinical and immunohistochemistry study before and after treatment.
    Chen SF; Chang CH; Kuo HC
    Spinal Cord; 2016 Oct; 54(10):889-894. PubMed ID: 26832760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
    Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
    Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurogenic detrusor overactivity: comparison between complete and incomplete spinal cord injury patients.
    Moslavac S; Dzidic I; Kejla Z
    Neurourol Urodyn; 2008; 27(6):504-6. PubMed ID: 18508334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Botulinum A toxin in the treatment of patients with detrusor external sphincter dyssynergia and neurogenic low detrusor contractility].
    Mazo EB; Krivoborodov GG; Efremov NS
    Ter Arkh; 2008; 80(10):49-52. PubMed ID: 19105415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction.
    Utomo E; Groen J; Blok BF
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD004927. PubMed ID: 24859260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions.
    Chancellor MB; Elovic E; Esquenazi A; Naumann M; Segal KR; Schiavo G; Smith CP; Ward AB
    Toxicon; 2013 Jun; 67():129-40. PubMed ID: 23415704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
    Denys P; Del Popolo G; Amarenco G; Karsenty G; Le Berre P; Padrazzi B; Picaut P;
    Neurourol Urodyn; 2017 Feb; 36(2):457-462. PubMed ID: 26756554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.
    Conte A; Giannantoni A; Proietti S; Giovannozzi S; Fabbrini G; Rossi A; Porena M; Berardelli A
    Eur J Neurol; 2012 May; 19(5):725-32. PubMed ID: 22212295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.
    Pannek J; Göcking K; Bersch U
    BJU Int; 2009 Nov; 104(9):1246-50. PubMed ID: 19426192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases.
    Do Ngoc Thanh C; Audry G; Forin V
    J Pediatr Urol; 2009 Dec; 5(6):430-6. PubMed ID: 19577520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.
    Reitz A; Stöhrer M; Kramer G; Del Popolo G; Chartier-Kastler E; Pannek J; Burgdörfer H; Göcking K; Madersbacher H; Schumacher S; Richter R; von Tobel J; Schurch B
    Eur Urol; 2004 Apr; 45(4):510-5. PubMed ID: 15041117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction.
    Akbar M; Abel R; Seyler TM; Bedke J; Haferkamp A; Gerner HJ; Möhring K
    BJU Int; 2007 Sep; 100(3):639-45. PubMed ID: 17532858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury.
    Patki PS; Hamid R; Arumugam K; Shah PJ; Craggs M
    BJU Int; 2006 Jul; 98(1):77-82. PubMed ID: 16831148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study.
    Krhut J; Samal V; Nemec D; Zvara P
    Spinal Cord; 2012 Dec; 50(12):904-7. PubMed ID: 22801191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
    Grosse J; Kramer G; Jakse G
    BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal effective dose of dysport and botox in a rat model of neurogenic detrusor overactivity.
    Behr-Roussel D; Oger S; Pignol B; Pham E; Le Maux A; Chabrier PE; Caisey S; Compagnie S; Picaut P; Bernabé J; Alexandre L; Giuliano F; Denys P
    Eur Urol; 2012 May; 61(5):1054-61. PubMed ID: 22341129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
    Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
    J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.